| Issuer | % of Class | Filed |
|---|---|---|
|
Lantern Pharma Inc.
13G/A
Amendment 1
LTRN · 51654W101
|
7.6% |
7/23/2026
Event 6/30/2026
|
|
Curis, Inc.
13G/A
Amendment 3
CRIS · 231269309
|
9.9% |
5/14/2026
Event 3/31/2026
|
|
inTest Corporation
13G/A
Amendment 3
INTT · 461147100
|
4.4% |
4/29/2026
Event 3/31/2026
|
|
Coherus Oncology, Inc.
13G/A
Amendment 1
CHRS · 19249H103
|
4.6% |
4/29/2026
Event 3/31/2026
|
|
Lantern Pharma Inc.
13G
LTRN · 51654W101
|
5.1% |
4/3/2026
Event 3/30/2026
|
|
Alico, Inc.
13G/A
Amendment 4
ALCO · 016230104
|
6.4% |
2/5/2026
Event 12/31/2025
|
|
enVVeno Medical Corporation
13G
NVNO · 29415J106
|
9.0% |
11/19/2025
Event 11/14/2025
|
|
BioCardia, Inc.
13G/A
Amendment 3
BCDA · 09060U606
|
9.9% |
8/13/2025
Event 6/30/2025
|
|
OS Therapies Incorporated
13G/A
Amendment 2
OSTX · 68764Y207
|
9.4% |
8/13/2025
Event 6/30/2025
|
|
Ark Restaurants Corp.
13G/A
Amendment 11
ARKR · 040712101
|
17.3% |
8/7/2025
Event 8/5/2025
|
|
inTest Corporation
13G/A
Amendment 2
INTT · 461147100
|
8.0% |
8/7/2025
Event 6/30/2025
|
|
Coherus BioSciences, Inc.
13G
CHRS · 19249H103
|
5.2% |
4/16/2025
Event 4/14/2025
|
|
Curis, Inc.
13G/A
Amendment 2
CRIS · 231269309
|
9.9% |
4/16/2025
Event 3/31/2025
|
|
Edesa Biotech, Inc.
13G/A
Amendment 2
EDSA · 27966L306
|
0% |
2/18/2025
Event 2/13/2025
|
|
OS Therapies Incorporated
13G/A
Amendment 1
OSTX · 68764Y207
|
5.9% |
2/12/2025
Event 12/31/2024
|
|
inTEST Corporation
13G/A
Amendment 1
INTT · 461147100
|
6.5% |
2/12/2025
Event 12/31/2024
|
|
Ark Restaurants Corp.
13G/A
Amendment 10
ARKR · 040712101
|
15.9% |
2/12/2025
Event 12/31/2024
|
|
Scientific Industries, Inc.
13G/A
Amendment 3
SCND · 808757108
|
9.9% |
2/12/2025
Event 12/31/2024
|
|
Edesa Biotech, Inc.
13G/A
Amendment 1
EDSA · 27966L306
|
6.7% |
2/12/2025
Event 12/31/2024
|
|
Curis, Inc.
13G/A
Amendment 1
CRIS · 231269309
|
9.1% |
2/12/2025
Event 12/31/2024
|
|
BioCardia, Inc.
13G/A
Amendment 2
BCDA · 09060U606
|
8.2% |
2/12/2025
Event 12/31/2024
|
|
CytoSorbents Corporation
13G
CTSO · 23283X206
|
6.6% |
1/17/2025
Event 1/13/2025
|
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.